Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter J Goebell

Showing results (81-90 of 107) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2004
Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinomaSunanda J Chatterjee, Ram Datar, David Youssefzadeh, et al.
Urologic Oncology|July 3, 2016
Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendationsWassim Kassouf, Samer L Traboulsi, Bernd Schmitz-Dräger, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Sensitivity and Specificity in Urine Bladder Cancer Markers - Is it that Simple?Florian Roghmann, Peter J Goebell, Lars Dyrskjøt, et al.
Urologic Oncology|November 27, 2022
25 years International Bladder Cancer Network (IBCN): The past, the present, and the futureLars Dyrskjøt, Antonia Vlahou, Peter C Black, et al.
International Journal of Colorectal Disease|June 18, 2010
Diagnostic challenge of atypical colorectal metastasis to the renal pelvisBastian Keck, Keck Bastian, Tilman Rau, et al.
International Journal of Cancer|October 18, 2020
Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trialMichael Staehler, Michael Stöckle, Daniel C Christoph, et al.
Urologic Oncology|February 10, 2021
Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray projectGang Wang, Peter C Black, Peter J Goebell, et al.
Urologic Oncology|November 27, 2022
IBCN Seminar Series 2021: Circulating tumor DNA in bladder cancerEmil Christensen, Alexander W Wyatt, Matthew D Galsky, et al.
Onkologie|March 15, 2013
Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional studyLothar Bergmann, Peter J Goebell, Ulrich Kube, et al.
Urologic Oncology|September 14, 2014
Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practiceBas W G van Rhijn, James W Catto, Peter J Goebell, et al.
Pageof 11

Showing results (81-90 of 107) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2004
Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinomaSunanda J Chatterjee, Ram Datar, David Youssefzadeh, et al.
Urologic Oncology|July 3, 2016
Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendationsWassim Kassouf, Samer L Traboulsi, Bernd Schmitz-Dräger, et al.
Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Sensitivity and Specificity in Urine Bladder Cancer Markers - Is it that Simple?Florian Roghmann, Peter J Goebell, Lars Dyrskjøt, et al.
Urologic Oncology|November 27, 2022
25 years International Bladder Cancer Network (IBCN): The past, the present, and the futureLars Dyrskjøt, Antonia Vlahou, Peter C Black, et al.
International Journal of Colorectal Disease|June 18, 2010
Diagnostic challenge of atypical colorectal metastasis to the renal pelvisBastian Keck, Keck Bastian, Tilman Rau, et al.
International Journal of Cancer|October 18, 2020
Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trialMichael Staehler, Michael Stöckle, Daniel C Christoph, et al.
Urologic Oncology|February 10, 2021
Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray projectGang Wang, Peter C Black, Peter J Goebell, et al.
Urologic Oncology|November 27, 2022
IBCN Seminar Series 2021: Circulating tumor DNA in bladder cancerEmil Christensen, Alexander W Wyatt, Matthew D Galsky, et al.
Onkologie|March 15, 2013
Everolimus in metastatic renal cell carcinoma after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy: results of an interim analysis of a non-interventional studyLothar Bergmann, Peter J Goebell, Ulrich Kube, et al.
Urologic Oncology|September 14, 2014
Molecular markers for urothelial bladder cancer prognosis: toward implementation in clinical practiceBas W G van Rhijn, James W Catto, Peter J Goebell, et al.
Pageof 11